Sanofi (NASDAQ:SNY) Cut to “Hold” at StockNews.com

Sanofi (NASDAQ:SNY) was downgraded by StockNews.com from a “buy” rating to a “hold” rating in a research note issued on Thursday.

Separately, Citigroup raised Sanofi to a “strong-buy” rating in a research note on Tuesday, September 17th. Two analysts have rated the stock with a hold rating, one has assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Sanofi has an average rating of “Moderate Buy” and a consensus target price of $57.50.

Sanofi Price Performance

SNY stock opened at $46.80 on Thursday. The firm has a market cap of $118.77 billion, a P/E ratio of 23.88, a P/E/G ratio of 1.24 and a beta of 0.58. The firm’s fifty day moving average is $51.02 and its 200 day moving average is $52.04. Sanofi has a 52 week low of $45.22 and a 52 week high of $58.97. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.65 and a current ratio of 1.00.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings data on Friday, October 25th. The company reported $1.57 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.22 by $1.35. Sanofi had a return on equity of 27.45% and a net margin of 9.96%. The firm had revenue of $13.44 billion for the quarter, compared to analysts’ expectations of $16.59 billion. During the same period last year, the firm earned $2.55 earnings per share. The company’s revenue for the quarter was up 12.3% compared to the same quarter last year. Research analysts predict that Sanofi will post 4.27 earnings per share for the current year.

Hedge Funds Weigh In On Sanofi

Several hedge funds and other institutional investors have recently modified their holdings of SNY. DGS Capital Management LLC increased its holdings in Sanofi by 4.2% during the 3rd quarter. DGS Capital Management LLC now owns 9,623 shares of the company’s stock valued at $555,000 after purchasing an additional 385 shares during the period. Logan Capital Management Inc. increased its stake in shares of Sanofi by 4.6% during the third quarter. Logan Capital Management Inc. now owns 85,189 shares of the company’s stock valued at $4,909,000 after buying an additional 3,774 shares during the period. Franklin Resources Inc. raised its holdings in shares of Sanofi by 13.1% during the third quarter. Franklin Resources Inc. now owns 3,407,452 shares of the company’s stock valued at $208,106,000 after acquiring an additional 395,744 shares in the last quarter. Tidal Investments LLC lifted its stake in Sanofi by 126.7% in the third quarter. Tidal Investments LLC now owns 13,798 shares of the company’s stock worth $795,000 after acquiring an additional 7,711 shares during the period. Finally, Wilmington Savings Fund Society FSB bought a new stake in Sanofi in the third quarter valued at $219,000. 14.04% of the stock is owned by institutional investors.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.